Setting a Course for Preventing Hepatitis E in Low and Lower-Middle-Income Countries: A Systematic Review of Burden and Risk Factors

Aybüke Koyuncu,1 Daniel Mapemba,2 Iza Ciglenecki,3 Emily S. Gurley,4 and Andrew S. Azman

1Independent Researcher, Atlanta, Georgia, USA, 2South African Field Epidemiology Training Program, National Institute for Communicable Diseases, Division of National Health Laboratory Services, Johannesburg, South Africa, 3Département d’Épidémiologie, International Rescue Committee, Geneva, Switzerland, 4Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA

**Background.** Hepatitis E virus (HEV) is responsible for outbreaks of acute jaundice in Africa and Asia, many of which occur among displaced people or in crisis settings. Although an efficacious vaccine for HEV has been developed, we lack key epidemiologic data needed to understand how best to use the vaccine for hepatitis E control in endemic countries.

**Methods.** We conducted a systematic review of articles published on hepatitis E in low-income and lower-middle-income countries in Africa and Asia. We searched PubMed, Scopus, and Embase databases to identify articles with data on anti-HEV immunoglobulin (Ig)G seroprevalence, outbreaks of HEV, or risk factors for HEV infection, disease, or death, and all relevant data were extracted. Using these data we describe the evidence around temporal and geographical distribution of HEV transmission and burden. We estimated pooled age-specific seroprevalence and assessed the consistency in risk factor estimates.

**Results.** We extracted data from 148 studies. Studies assessing anti-HEV IgG antibodies used 18 different commercial assays. Most cases of hepatitis E during outbreaks were not confirmed. Risk factor data suggested an increased likelihood of current or recent HEV infection and disease associated with fecal-oral transmission of HEV, as well as exposures to blood and animals.

**Conclusions.** Heterogeneity in diagnostic assays used and exposure and outcome assessment methods hinder public health efforts to quantify burden of disease and evaluate interventions over time and space. Prevention tools such as vaccines are available, but they require a unified global strategy for hepatitis E control to justify widespread use.

**Keywords:** hepatitis E; hepatitis E virus (HEV); outbreaks; risk factors; seroprevalence.

Hepatitis E virus (HEV) is a single-stranded ribonucleic acid (RNA) virus that causes over 3 million cases of symptomatic hepatitis each year [1]. The global burden of HEV is predominantly attributable to genotypes 1 and 2, which are associated with sporadically occurring cases as well as large protracted outbreaks in low- and middle-income countries where access to clean water and sanitation is limited [1, 2]. Hepatitis E virus outbreaks disproportionately affect pregnant women, for whom the mortality rate due to hepatitis E has been reported to be as high as 25% [3].

Although outbreaks of HEV genotypes 1 and 2 in low and lower-middle-income countries (LMICs) are caused by fecal contamination of drinking water, transmission of other HEV genotypes, predominantly 3 and 4, can cause acute sporadic cases of hepatitis. Genotypes 3 and 4 are nonepidemic and are known to circulate in animal reservoirs and can be spread through zoonotic transmission, consumption of raw or undercooked meat, blood transfusions, and organ donation [2–4]. Although acute sporadic cases of HEV in high-income countries are typically associated with genotypes 3 and 4, the burden of these genotypes in LMICs remains unclear [2].

Access to clean water and sanitation could significantly reduce the transmission of HEV in LMICs, but household-level water and sanitation interventions often require behavioral change and have had mixed results in outbreak control [5]. Outbreaks of HEV, many of which occur among displaced people or in crisis settings, are notoriously difficult to control in part due to the high proportion of asymptomatic and mildly symptomatic infections and limited options for clinical management of severe cases [3]. One potential intervention strategy to control HEV transmission is a recombinant vaccine, HEV239 (Hecolin; Innovax, Xiamen, China), which has been shown to be safe and highly efficacious in preventing HEV infection due to genotype 4, with pan-genotype protection expected [6]. The World Health Organization (WHO) has not recommended the routine use of the vaccine in HEV-endemic countries, citing a critical lack of epidemiologic data on the incidence of disease.
in the general population and in special subpopulations [7]. In the absence of these data, Hecolin is currently only recommended by the WHO for consideration during HEV outbreaks, although at the time of writing this it has not been used in any outbreaks [7].

Burden-of-disease data, combined with information on key risk factors for HEV infection and disease, can spur the use of existing prevention tools that may be capable of substantially reducing morbidity and mortality due to HEV in LMICs. A lack of data on the burden and transmission patterns of HEV precludes investments into a global strategy for control for hepatitis E [8].

Given the clear pathway for WHO prequalification of the existing vaccine [9], a better understanding of the epidemiology of hepatitis E viruses is needed to set the agenda for global strategy and identify best practices to measure impact. In this study, we aim to review data on the epidemiology of hepatitis E in LMICs in Africa and Asia through systematic reviews of 3 domains of evidence: first, through a review of seroprevalence studies; second, a review of reported outbreak size and geography; and third, a review of risk factors for infection, disease, and death.

METHODS

Search Strategy
We searched PubMed, Scopus, and Embase to identify all studies with “hepatitis E” in the article title that were published before November 2018, regardless of language. We uploaded search results to Covidence (www.covidence.org), which we used to manage the subsequent steps of the review.

Study Selection
For both stages of study selection (abstract review, full-text review), 2 independent reviewers screened each document for eligibility. All discrepancies between reviewers were reviewed by a third reviewer, who discussed with the original reviewers and decided upon the correct classification.

Studies were included if they satisfied the following inclusion criteria: (1) study in a low-income or lower-middle-income country in Africa or Asia according to 2019 World Bank country classifications [10]; and (2) includes serosurvey data (anti-HEV immunoglobulin [Ig]G only, IgG and/or IgM) in populations without known liver disease; or (3) includes an outbreak description of HEV genotype 1, 2, or unidentified genotype; or (4) includes effect size estimates (eg, odds ratio, risk ratio) for potential risk factors for current or recent infection (anti-HEV IgM or RNA), disease, or death.

Studies were excluded if they met any of the following criteria: (1) abstract or full text not available; (2) abstract or full text not in French, English, or Spanish; (3) nonhuman study of HEV; (4) diagnostic, viral genetics, or immunologic study; (5) case series with no controls for any outcome; (6) commentary, perspective, or review article; (7) studies with duplicate data.

Data Extraction
A data extraction form developed by the authors was used to extract data from the full text of all included studies. A plot digitizer (https://apps.automeris.io/wpd/) was used if data were only presented graphically. To gauge the consistency of the data extraction and to identify common errors, 10% of all studies in the data abstraction phase were extracted independently by 2 reviewers, and any discrepancies in data extracted were resolved by discussion and consensus. We used lessons from discrepancies in extracted data to adjust previous extractions and to ensure that future extractions did not have those errors.

Seroprevalence Studies
For studies reporting seroprevalence data, we extracted population type, lower and upper bounds for population age, diagnostic assay, test isotype (anti-HEV IgG or IgG+IgM), and the total number of samples tested and number of positive and/or negative samples. Within each study, data were extracted separately for each age stratum and unique population type: general population; blood donors; patients attending a hospital or clinic for nonliver-related, nonpregnancy-related issues; pregnant women; occupational groups exposed to animals (eg, butchers, pig farmers); outbreak residents (ie, individuals identified in areas with an ongoing HEV outbreak); or other. Refugee and internally displaced populations that were not experiencing outbreaks were categorized as “other.” If studies reported seroprevalence data from the same population using different assays including Wantai assays (Wantai BioPharm, Beijing, China; considered the most reliable commercially available assay at the time of writing), we only extracted seroprevalence data based on Wantai assays [11].

Outbreak Descriptions
For studies describing outbreaks, we extracted the date of the first and last cases reported in the outbreak, whether the outbreak occurred in a refugee or displaced persons camp, HEV genotype(s) identified, suspected and/or confirmed case definitions and laboratory-confirmation methods, number of suspected cases with confirmatory testing, average age (mean or median) of cases, number of suspected and/or confirmed cases, and number of suspected and/or confirmed deaths. Data on the number of suspected and/or confirmed cases and deaths were extracted within stratum of where cases were identified, namely, the following: at health facilities, in communities, in institutions (eg, prisons, army barracks), and not reported. The number of suspected and/or confirmed cases and deaths was extracted for the general population and also separately for pregnant and/or postpartum women and children under the age of 5. If multiple studies described the same outbreak (overlapping outbreak dates in the same geographic area and population), the most comprehensive outbreak report was extracted. Studies describing the same outbreak were combined only if they presented unique data (eg, data on different subpopulations, number of deaths, etc).
Risk Factors
For studies including risk factors for infection, disease, or death, we extracted outcome definition and confirmation method, estimator of association (eg, odds ratio, risk ratio), effect size, 95% confidence interval, reference category for the estimator, and whether the estimator was adjusted for any covariates using regression analysis or matching. If both odds ratios and risk ratios were presented for the same risk factor, we extracted odds ratios. If risk factor data were reported for different case definitions of infection/disease within the same study, we extracted the most conservative case definition. We categorized each risk factor into one of the following groups: water, sanitation, hygiene, food and drink (nonwater), exposure to blood or blood products, exposure to animals, age, sex, education, household composition, or other. Current and recent HEV infection and disease was defined in 3 categories: serologic evidence of anti-HEV IgM or RNA with accompanying symptoms (“confirmed infection”), symptoms consistent with hepatitis (eg, jaundice, elevated liver enzymes) without any serologic testing (“suspected disease”), or symptoms consistent with hepatitis with confirmation by IgM or HEV RNA (“confirmed disease”).

Data Analysis
We examined trends in the number of seroprevalence studies conducted over time, as well as variability in seroprevalence by age, population type, and diagnostic assay. Age-specific seroprevalence was calculated using the median age of tested individuals for each seroprevalence estimate. Seroprevalence estimates with no data on population age were excluded from analysis of seroprevalence by age.

We estimated outbreak duration using the difference between the date of the first and last cases reported in each outbreak description. The case fatality risk (CFR) was calculated separately among suspected cases and confirmed cases, and this was defined as the number of suspected and/or confirmed deaths divided by the number of suspected and/or confirmed cases.

We categorized risk factors based on the general consensus of the literature on factors that increase HEV infection/disease/death risk and those that are protective. Risk factors lacking a hypothesized direction of effect (eg, ethnicity) or with an unspecified reference group were excluded from further analysis. Factors were categorized as increased risk factors if the reference category for their effect estimator was no exposure or less exposure to factors hypothesized to increase the likelihood of HEV infection, disease, or death. Household water sources and type of sanitation facilities were categorized as improved or unimproved according to 2019 World Health Organization/United Nations Children’s Fund standard categories [12]. A summary of risk factors and their corresponding exposures hypothesized to increase the likelihood of HEV infection/disease/death is provided in the Appendix (Supplemental Table 1). If studies reported unadjusted and adjusted estimates, we included the adjusted estimates. We examined the proportion of risk factors that followed the hypothesized direction of effect (eg, effect estimate >1 for risk factors hypothesized to increase risk) and the proportions that were statistically significant based on 95% confidence intervals or a P < .05.

Data Availability
All data from published literature included in this systematic review are available at https://github.com/akoyuncu4/hepatitis-E-in-LMIC-a-systematic-review.git.

RESULTS
After the exclusion of duplicates, our search identified 4928 studies for abstract screening, 666 of which met the criteria for full-text review. We identified 148 studies that satisfied the inclusion criteria after full-text review (Figure 1).

Seroprevalence
We identified 91 studies with seroprevalence data [13–103] from 29 countries, with serum collected between 1978 and 2017 (Figure 2). Among studies that reported assay manufacturer (85%; 77 of 91), anti-HEV IgG antibodies were assessed using 18 different commercial assays as well as in-house assays (eg, Walter Reed Army Institute of Research in-house assay). The most common assays used to assess seroprevalence were in-house assays (21%) [14, 34, 44, 47, 51, 53, 56, 60, 61, 70, 72, 79, 84, 91, 97, 100], Wantai (18%; Wantai BioPharm, Beijing, China) [20–23, 31, 40, 46, 48, 54, 59, 63, 65, 76, 77], and Abbott (14%; Abbott Diagnostika, Germany) [15, 18, 28, 32, 43, 80, 82, 83, 87, 93, 94], with the Wantai assay becoming the most commonly used assay in studies conducted in the last 5 years of the review (2013–2017).

Hepatitis E virus seropositivity, in general, increased with age among all population groups except occupational groups exposed to animals (Figure 3). Age-specific seroprevalence estimates, excluding occupational groups and outbreak residents, increased by age with all assays used, except Abbott (Supplemental Figure 1).

Outbreaks
We identified 51 outbreak reports [30, 50, 78, 82, 85, 93, 104–148] describing 49 completed or ongoing outbreaks occurring in 18 countries between 1988 and 2017. Among outbreaks with reported locations (48 of 49), outbreaks were identified in Africa (43%) and Asia (57%), with over half of outbreaks reported from 3 countries: India (35%) [30, 106, 107, 109, 110, 114, 117, 121, 125, 128, 136–138, 141, 145, 147, 148], Sudan (10%) [119, 133, 140, 143, 144], and Uganda (8%)
Reported outbreak durations ranged from 28 days (Yangon, Myanmar) [142] to 3.2 years (Karamoja region, Uganda) [126] (median, 166 days; interquartile range [IQR], 91–303). At least 1 large-scale outbreak with over 5000 suspected cases occurred in every decade since 1988, and outbreaks in the last 15 years (2004–2017) had a median of 1152 suspected cases reported (IQR, 252–2362). Among all outbreaks, 12% occurred in refugee camp and/or informal settlements (N = 6) [50, 78, 111, 119, 123], with 31% of all suspected cases (24,341 of 77,372 suspected cases) identified in our review occurring in these settings.

Confirmatory serologic testing (ie, IgM) was conducted for 10% of all suspected cases reported in outbreaks (7956 of 77,372), including 15 small outbreaks (<500 suspected cases) in which 100% of all suspected cases had confirmatory serologic testing [30, 82, 93, 113, 118, 121, 122, 125, 129, 134, 135, 140, 142–144]. Among outbreaks where at least some cases were laboratory confirmed (N = 47), 94% of confirmed case definitions included serologic confirmation of HEV IgM and 21% included HEV RNA. Overall, 43% of all suspected cases were identified in health facilities, 42% were identified within the community, 1% were identified in institutions (eg, military training camps, prisons), and 13% were identified in unknown locations.

Among studies reporting data on deaths (34 of 49), the CFR ranged from 0% to 28% among suspected cases (mean = 2, standard deviation [SD] = 6) and 0%–28% among confirmed cases (mean = 3, SD = 7). Fewer outbreak reports had available data on deaths among pregnant women (20 of 48), and the CFR among pregnant women ranged from 0% to 33% among suspected cases (mean = 11, SD = 10) and 0%–65% among confirmed cases (mean = 28, SD = 24) [50, 78, 82, 104, 106, 108, 112–114, 117, 119, 120, 123, 124, 126–129, 140, 146]. The highest CFR (65%; 15 fatalities among 23 confirmed pregnant cases) was reported among pregnant women in an outbreak in Napak district, Uganda, which had over 1300 confirmed cases of HEV in the overall population in 2013–2014 [108].
Data on risk factors for HEV infection (defined by IgM antibodies or RNA), disease, and death were identified in 36 studies [17, 21, 26, 30, 34, 46, 63, 68, 74, 85, 91, 92, 102, 104, 108–110, 112, 116, 129, 138, 139, 145–158] from 13 countries between 1990 and 2017. One study only reported risk factors with an unknown hypothesized direction of effect and was excluded from further analysis [159]. We identified only 2 studies [112, 154] that examined risk factors for death and decided not to further summarize these limited data. Risk factors were predominantly for confirmed disease (65%; 182 of 279), confirmed infection (25%; 70 of 279), followed by suspected disease (8%; 23 of 279), and a mixture of suspected and/or confirmed disease (1%; 4 of 279). Studies investigating risk factors occurred in Africa (41%) and Asia (59%), and 33% of all individual risk factor estimates came from studies conducted in Bangladesh [112, 139, 151, 158]. Most risk factor estimates included 95% confidence intervals (97%; 270 of 279) and were not adjusted for other covariates (74%; 206 of 279). The most common risk factors examined were those categorized as other (29 of 68) were related to demographics and socioeconomic status ([SES] eg, rural residence, household size, etc) (Supplementary Table 1). Risk factors related to water included household sources of water for drinking, cooking, or bathing, and water treatment and storage methods. Forty-six percent of all studies investigating risk factors (16 of 35) were from HEV outbreaks [30, 85, 104, 108–110, 112, 116, 119, 129, 138, 139, 145–148].

Based on the direction of effect estimates, 67% of effect estimates for water suggested increased risk of HEV with increased exposure to unimproved water sources, and 33% of estimates showed the opposite trend or no effect (effect size = 0) (Figure 4). Effect estimates for sanitation and hygiene were similarly heterogeneous: 83% of sanitation-related estimates suggested increased risk with exposure to unimproved sanitation, and 71% of hygiene-related effect estimates suggested increased risk due to poor hygiene practices (eg, never washing hands after defecating, etc). Among estimates reported with a measure of statistical significance (76 of 79), a higher proportion of estimates for sanitation were statistically significant (33%) compared with estimates for water (21%) or hygiene (29%).
Increased risk of HEV infection and/or disease (effect size > 1) was identified in a majority of effect estimates related to exposures to food and drink (82% of estimates), blood (81%), and animals (72%). Food and drink exposures (N = 33) were predominantly assessed with questions related to consumption of meat (42%) and juices and/or sodas (24%). The majority of assessed exposures to blood (N = 16) were related to blood transfusions (38%) and recent injections (25%). The majority of assessed exposures to animals (N = 25) were related to the presence of animals (pets or varmints) in compounds and/or homes (32%), occupational exposures (24%), any contact with animals (16%), and livestock ownership (16%). Only 21% (7 of 33) of effect estimates related to food and/or drink exposures were statistically significant, whereas 38% (6 of 16) of estimates for blood exposures and 20% (5 of 25) of estimates for animal exposures were significant.

The directionality of effect estimates was consistent with the hypothesis that older age increases risk of HEV disease and/or infection in 52% of estimates for confirmed disease and 54%
of estimates for confirmed infection, as would be expected by chance. Effect estimates related to age were statistically significant for 40% (10 of 25) of estimates for confirmed disease and 8% (1 of 12) of estimates for confirmed infection. Eighty-two percent (9 of 11) of estimates that were statistically significant suggested increased risk for confirmed HEV disease and/or infection with older age.

In 72% of estimates (13 of 18), males had a higher risk of infection and/or disease than females. Among estimates reported with a measure of statistical significance (17 of 18), 41% were statistically significant.

**DISCUSSION**

Through a synthesis of published literature, we highlight the persistent burden of hepatitis E genotypes 1 and 2 in LMICs and suggest that in addition to fecal-oral transmission, zoonotic and bloodborne transmission may also be contributing to this
burden. Although studies on HEV burden have expanded geographically over time, existing data are insufficient to identify temporal or geographic trends in risk. Similar to other reviews, we note challenges in interpreting and comparing data from different studies due to variability in diagnostic assays used, definitions of suspected and confirmed cases of HEV [160–162], and lack of standardized age groups used in analysis. Unified guidance and best practices for measuring disease burden and risk factors are urgently needed to generate evidence needed for developing a global strategy for hepatitis E control.

Given that most cases of hepatitis E are mild or asymptomatic, and given the lack of routine testing for hepatitis E among acute jaundice cases in LMICs, our knowledge on HEV burden of disease is largely limited to special studies and outbreak reports [163]. Gaps in burden of disease data identified by WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) in 2015 as barriers to widespread introduction of hepatitis E vaccine remain largely unaddressed [7]. A lack of data on the incidence of disease in the general population prevents the necessary investments in hepatitis E surveillance infrastructure, which cyclically limits our ability to quantify disease burden and advocate for expanded use of the existing vaccine. It is notable that the severe acute respiratory syndrome coronavirus 2 pandemic provides an opportunity to break this cycle due to the increased number of representative population-based surveys that have been conducted [164]. Leveraging remnant samples from these studies could provide a cost-effective way of greatly increasing our understanding of the global burden of hepatitis E [165].

Our findings emphasize how a reliance on data from outbreak reports can obscure potentially important HEV transmission pathways. Trends suggestive of increased risk for infection and disease due to exposures to animals and consumption of meat suggest that HEV genotypes 3 and 4 may be responsible for some of the hepatitis E burden. Our findings suggest that sporadic hepatitis cases in LMICs may also be due to bloodborne transmission of HEV, which is most likely to be caused by the predominant circulating genotype within each population [151]. However, our ability to draw conclusions about the role of zoonotic and bloodborne transmission is limited given that only 27% of studies with data on risk factors adjusted for potentially confounding variables such as SES and we did not identify an association between age and seropositivity among those with occupational exposures to animals. Our ability to identify key risk factors is further limited by the fact that most “controls” in case-control studies were recruited on the basis of not having hepatitis E disease with the assumption that they were still at-risk. Some of these controls were almost certainly previously exposed to HEV, which would lead to reduced power, and in some cases bias, in estimates of risk factors [166]. A better understanding of the frequency of HEV infection due to transmission routes such as zoonotic transmission and bloodborne transmission in endemic countries may justify potentially life-saving interventions such as blood donor screening for HEV.

The WHO has recommended the vaccine be considered as a strategy to prevent and mitigate outbreaks, particularly among high-risk groups such as pregnant women [7]. The current vaccine’s 3-dose schedule given across 6 months introduces logistical constraints to rapidly deploying vaccines in outbreaks [167]. Although reduced dose regimens may confer protection against HEV [6], the multiyear protracted outbreaks identified in our review suggest the potential for even a 3-dose regimen to substantially prevent morbidity and mortality among the world’s most vulnerable populations. Although the vaccine is currently only recommended for use among those aged 16 and above, understanding the role of young children in household and community HEV transmission is critical to developing rational vaccination strategies. We did not identify meaningful differences between the association between age and HEV infection and/or disease stratified by symptomatic versus asymptomatic infections, but we identified populations of young children with high seroprevalence of historic HEV infection. Although we note that CFRs may be overestimated in studies relying on health facilities for case detection, the average case fatality risk among confirmed pregnant cases in outbreaks in this review was 9.3 times higher than confirmed cases in the general population. Field studies are urgently needed to evaluate the safety and effectiveness of the existing hepatitis E vaccine subpopulations such as refugees and pregnant women who are disproportionately affected by the burden of HEV.

This review has several limitations. We did not conduct any formal risk of bias assessments, and we did not exclude any studies on the basis of sample size. Trends in risk factor data may have been under- or overestimated due to the inclusion of low-quality estimates. We underestimated the number of HEV outbreaks in LMICs due to limited publishing of outbreaks in peer-reviewed journals and our exclusion of less formal outbreak reports, such as the WHO Outbreaks and Emergencies bulletin. Outbreak reports were often based on research investigations of outbreak etiology rather than comprehensive assessments of outbreak size, leading to an underestimation of the burden of outbreaks. Age-specific seroprevalence curves stratified by population type were generated using data from diverse diagnostic assays, which have varying sensitivity and specificity, and therefore may not represent true age-specific patterns. Finally, our ability to draw conclusions from risk factor data is limited given our inclusion of unadjusted and adjusted estimators collected from varying population types. Nevertheless, we identify key trends in the force of infection of HEV and risk factors for transmission that warrant further investigation in future studies.
CONCLUSIONS

Addressing outstanding gaps in our understanding of the epidemiology of HEV in LMICs is critical to justify the funds needed for expanded use of the vaccine after prequalification. Standardized guidelines defining best practices for study design and exposure and outcome measurement in hepatitis E research are needed to identify key areas with elevated incidence of HEV infection where the vaccine may be a cost-effective tool to prevent avoidable morbidity and mortality. Guidelines are also needed to define a minimum set of risk factors for which data should be collected in all HEV outbreak investigations and risk factor studies, including the following: sociodemographic variables (eg, SES, age, sex); water, sanitation, and hygiene; and exposures to animals and blood. Broad control of hepatitis E with existing tools and strategies is possible, but it requires a unified global strategy and the inclusion of hepatitis E in the agendas of researchers, public health authorities, and funders.

Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Supplemental Figure 1. Age seroprevalence curves by assay in 29 countries, 1978–2017. Excludes seroprevalence estimates from occupational groups exposed to animals and residents of outbreak affected areas, seroprevalence estimates with no specified age bounds, 6 studies with unspecified study year, and 1 study with unspecified study location. Black line represents the best-fit linear trend between age and seropositivity. NIH, National Institutes of Health.

Acknowledgments
Author contributions. A. S. A., E. S. G., and I. C. conceptualized and oversaw the development of the manuscript. A. K., D. M., E. S. G., and A. S. A. searched and reviewed the literature and A. K., D. M., and A. S. A. abstracted data. A. K. conducted the formal analysis and wrote the original manuscript draft. All authors reviewed the results, edited the manuscript, and approved the final manuscript.

Disclaimer. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Financial support. This work was funded by the Bill & Melinda Gates Foundation (INV-0166643; to A. S. A.).

Potential conflicts of interest. All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

References
1. Rein DB, Stevens GA, Theaker J, et al. The global burden of hepatitis E virus genotypes 1 and 2 in 2005. Hepatology 2012; 55:988–97.
2. World Health Organization. The Global Prevalence of Hepatitis E Virus Infection and Susceptibility: A Systematic Review. Geneva, Switzerland: World Health Organization; 2010.
3. Kamar N, Bendall R, Legrand-Abreavanel F, et al. Hepatitis E. Lancet 2012; 379:2477–88.
4. Purcell RH, Emerson SU. Hepatitis E: an emerging awareness of an old disease. J Hepatol 2005; 48:494–503.
5. Guttermann JP, Klovstad H, Boccia D, et al. A large outbreak of hepatitis E among a displaced population in Darfur, Sudan, 2004: the role of water treatment methods. Clin Infect Dis 2006; 42:1685–91.
6. Zhu FC, Zhang J, Zhang XF, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 2010; 376:895–902.
7. World Health Organization. Hepatitis E vaccine: WHO position paper. Wkly Epidemiol Rec 2015; 90:185–200.
8. Cooper BS, White LJ, Siddiqui R. Reactive and pre-emptive vaccination strategies to control hepatitis E infection in emergency and refugee settings: a modelling study. PLoS Negl Trop Dis 2018; 12:e0006807.
9. World Health Organization. Recommendations to assure the quality and efficacy of recombinant hepatitis E vaccines. Available at: https://www.who.int/biologicals/expert_committee/POST_ECBS_2018_Recommendations_HEV_vaccines.pdf?ua=1. Accessed 1 October 2020.
10. World Bank Country and Lending Groups. World Bank data help desk. Available at: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups. Accessed 1 October 2020.
11. Kmush BL, Labrique AB, Dalton HR, et al. Two generations of “Gold Standards”: the impact of a decade in hepatitis E virus testing innovation on population seroprevalence. Am J Trop Med Hyg 2015; 93:714–7.
12. United Nations Children’s Fund (UNICEF), World Health Organization. Progress on Household Drinking Water, Sanitation and Hygiene 2000–2017: Special Focus on Inequalities. New York: World Health Organization; 2019. https://www.who.int/water_sanitation_health/publications/jmp-report-2019/en/
13. Adjei AA, Tettey Y, Aviyase JT, et al. Unexpected elevated alanine aminotransferase, aspartate aminotransferase levels and hepatitis E virus infection among persons who work with pigs in accra, Ghana. Virol J 2010; 7:336.
14. Kmush BL, Labrique A, Li W, et al. The association of cytokines and micronutrients with hepatitis E virus infection during pregnancy and the postpartum period in rural Bangladesh. Am J Trop Med Hyg 2016; 94:203–11.
15. Khuroo MS, Rustgi VK, Dawson GI, et al. Spectrum of hepatitis E virus infection in India. J Med Virol 1994; 43:281–6.
16. Vivek R, Chandy GM, Brown DW, Kang S. Seroprevalence of IgG antibodies to hepatitis E in urban and southern India. Trans R Soc Trop Med Hyg 2010; 104:307–8.
17. Houcine N, Jacques R, Salma F, et al. Seroprevalence of hepatitis E virus infection in rural and urban populations, Tunisia. Clin Microbiol Infect 2012; 18:1E19–21.
18. Aubry P, Niel L, Niyongabo T, et al. Seroprevalence of hepatitis E virus in an adult urban population from Burundi. Am J Trop Med Hyg 1997; 57:272–3.
19. Jafari W, Yakoob J, Abid S, et al. Seroprevalence of hepatitis E and Helicobacter pylori in a low socioeconomic area of a metropolitan city in a developing country. Br J Biomed Sci 2013; 70:27–30.
20. Taha TE, Rusie LK, Labrique A, et al. Seroprevalence for hepatitis E and other viral hepatitis in urban, semi-urban and rural communities of Nigeria. Vaccine 2014; 32:5777–82.
21. Kamel MA, Troonen H, Kapprell HP, et al. Seroepidemiology of hepatitis E virus in urban and rural southern India. Trans R Soc Trop Med Hyg 2010; 3:496–500.
22. Abebe M, Ali I, Ayele S, et al. Seroprevalence and risk factors of hepatitis E virus infection among pregnant women in Addis Ababa, Ethiopia. PloS One 2017; 12:e0180078.
23. Niguse S, Hailmekos H, Buruh G, et al. Seroprevalence and risk factors of hepatitis E virus infection among pregnant women attending antenatal care in health facilities of Tigray, Northern Ethiopia. J Med Virol 2018; 90:1364–9.
24. Hannachi N, Hidar S, Harrabi I, et al. [Seroprevalence and risk factors of hepatitis E among pregnant women in central Tunisia]. Pathol Biol (Paris) 2011; 59:113–8.
25. Ekanem E, Ikobah J, Okpara H, Udo I. Seroepidemiology and predictors of hepatitis E infection in Nigerian children. J Infect Dev Ctries 2015; 9:116–22.
26. Furukawa NW, Teshale EH, Cosmas L, et al. Serologic evidence for hepatitis E virus infection among patients with undifferentiated acute febrile illness in Kibera, Kenya. J Clin Virol 2016; 77:106–8.
27. Jacobs C, Chihuba C, Phiri C, et al. Seroepidemiology of hepatitis E virus infection in an urban population in Zambia: strong association with HIV and environmental enteropathy. J Infect Dis 2014; 209:652–7.
28. Kamel MA, Troonen H, Kapprell HP, et al. Seroepidemiology of hepatitis E virus in the Egyptian Nile Delta. J Med Virol 1995; 47:399–403.
29. Bawazir AA, Mawash A, Sallam TA, et al. Seroepidemiology of hepatitis A and hepatitis E viruses in Aden, Yemen. Trans R Soc Trop Med Hyg 2010; 104:801–5.
30. Khuroo MS, Khuroo MS. Seroepidemiology of a second epidemic of hepatitis E in a population that had recorded first epidemic 30 years before and has been under surveillance since then. Hepatol Int 2010; 4:494–9.
31. Bansal M, Kaur S, Deka D, et al. Seroepidemiology and molecular characterization of hepatitis E virus infection in swine and occupationally exposed workers in Punjab, India. Zoonoses Public Health 2017; 64:662–72.
32. Benjelloun S, Boubhouri B, Bouchrit N, et al. Seroepidemiological study of an acute hepatitis E outbreak in Morocco. Res Virol 1997; 148:287–97.
33. Obari-Yeboah D, Asante Awooku Y, Adu J, et al. Sero-prevalence and risk factors for hepatitis E virus infection among pregnant women in the Cape Coast Metropolis, Ghana. PLoS One 2018; 13:e0191685.
34. Mathur P, Azarova NK, Panda SK, et al. Sero-epidemiology of hepatitis E virus (HEV) in urban and rural children of North India. Indian Pediatr 2001; 38:429–32.
35. Das K, Agarwal A, Andrew R, et al. Role of hepatitis E and other enterotropic viruses in aetiology of sporadic acute viral hepatitis: a hospital based study from urban Delhi. Eur J Epidemiol 2000; 16:937–40.
36. Abdel Rahman MM, Massoud AM, Kamel MA, et al. Risk of hepatitis E” virus infection among these schistosomiasis patients in Egypt. J Egypt Soc Parasitol 1999; 29:115–21.
37. Cawston T, Safiullah S, Nicand E. Risk of enterically transmitted hepatitis A, hepatitis E, and Plasmodium falciparum malaria in Afghanistan. Clin Infect Dis 2009; 48:1800.
38. Aranakale VA, Chobe LP. Retrospective analysis of blood transfusion recipients: evidence for post-transfusion hepatitis E. Vox Sang 2000; 79:72–4.
39. Clayson ET, Shrestha MP, Vaughn DW, et al. Rates of hepatitis E virus infection and disease among adolescents and adults in Kathmandu, Nepal. J Infect Dis 1997; 176:563–6.
40. Katiyar H, Goel A, Sonker A, et al. Prevalence of hepatitis E virus viremia and antibodies among healthy blood donors in India. Indian J Gastroenterol 2018; 37:342–6.
41. Chandra NS, Ojha D, Chatterjee S, Chattopadhyay D. Prevalence of hepatitis E virus infection in West Bengal, India: a hospital-based study. J Med Microbiol 2014; 63:975–80.
42. Utsumi T, Hayashi Y, Lasida MI, et al. Prevalence of hepatitis E virus in bloodborne hepatitis outbreak. J Med Virol 2010; 37:58–60.
43. Carmo T, Safiullah S, Nicand E. Risk of enterically transmitted hepatitis A, hepatitis E, and Plasmodium falciparum malaria in Afghanistan. Clin Infect Dis 2009; 48:1800.
44. Martinson FE, Marfo YV, Degaaf J. Hepatitis E virus seroprevalence in children living in rural Ghana. West Afr J Med 1999; 18:76–9.
45. Boon D, Reed AD, Laeyendecker O, et al.; Rakai Health Sciences Program. Hepatitis E virus seroprevalence and correlates of anti-HEV IgG antibodies in the Rakai District, Uganda. J Infect Dis 2018; 217:785–9.
46. Ben-Ayed Y, Hannachi H, Ben-Alaya-Bouaif N, et al. Hepatitis E virus seroprevalence among hemodialysis and hemophiliac patients in Tunisia (North Africa). J Med Virol 2015; 87:441–5.
47. Shrestha AC, Flower RL, Seed CR, et al. Hepatitis E virus seroepidemiology: a post-earthquake study among blood donors in Nepal. BMC Infect Dis 2016; 16:707.
48. Caron M, Karanj M. Hepatitis E virus is highly prevalent among pregnant women in Gabon, central Africa, with different patterns between rural and urban areas. Virol J 2008; 5:158.
49. Vivek R, Kang G. Hepatitis E virus infections in swine and swine handlers in Vellore, Southern India. Am J Trop Med Hyg 2011; 84:647–9.
50. Feldt T, Sarfo FS, Zoufaly A, et al. Hepatitis E virus infections in HIV-infected patients in Ghana and Cameroon. J Clin Virol 2013; 58:18–23.
51. Patel RC, Kamili S, Thesala E. Hepatitis E virus infections in children age 0–15, Uganda outbreak, 2007. J Clin Virol 2015; 73:112–4.
52. Khuroo MS, Kamili S, Yatoo GN. Hepatitis E virus infection may be transmitted through blood transfusions in an endemic area. J Gastroenterol Hepatol 2004; 19:778–84.
53. Adjei AA, Tettey Y, Aviyase JT, et al. Hepatitis E virus infection is highly prevalent among pregnant women in Accra, Ghana. Virol J 2009; 6:108.
54. Myint KS, Duripunt P, Mammen MP Jr, et al. Hepatitis E virus infection in Thai troops deployed with U.N. peacekeeping forces. Mil Med 2007; 172:1217–9.
55. Meldal BH, Sarkodie I, Owusu-Ofori S, Allain JP. Hepatitis E virus infection in Ghanaian blood donors - the importance of immunosassay selection and confirmation. Vox Sang 2013; 104:30–6.
56. Sheikh A, Sagitani M, Kimukawa N, et al. Hepatitis E virus infection in endemic hepatitis patients and an apparently healthy population in Bangladesh. Am J Trop Med Hyg 2002; 66:721–4.
57. Shimakawa Y, Nijai HF, Takahashi K, et al. Hepatitis E virus infection and acute-on-chronic liver failure in West Africa: a case-control study from The Gambia. Aliment Pharmacol Ther 2014; 41:375–84.
58. Adjei AA, Aviyase JT, Tettey Y, et al. Hepatitis E virus infection among pig handlers in Accra, Ghana. East Afr Med J 2009; 86:359–63.
59. Mohamed SY, Emam EA, Omar AA, Al-Aziz Gaber OA. Hepatitis E virus IgG in serum of pregnant women. J Gastroenterol Hepatol Res 2017; 6:2435–40.
60. Harristhøj LH, Thielgaard ZP, Mannheimer E, et al. Hepatitis E virus epidemiology among HIV-infected women in an urban area in Tanzania. Int J Infect Dis 2018; 73:7–9.
61. Nouhin J, Prak S, Madec Y, et al. Hepatitis E virus antibodies prevalence, RNA frequency, and genotype among blood donors in Cambodia (Southeast Asia). Transfusion 2016; 56:2597–601.
62. Teshale EH, Howard CM, Grytdal SP, et al. Hepatitis E epidemic, Uganda. Emerg Infect Dis 2010; 16:126–9.
63. Stozsek SK, Engle RE, Abdel-Hamid M, et al. Hepatitis E antibody seroconversion without disease in highly endemic rural Egyptian communities. Trans R Soc Trop Med Hyg 2006; 100:89–94.
64. Amer AF, Zaki SA, Nagati AM, Darwish MA. Hepatitis E antibodies in Egyptian adolescent females: their prevalence and possible relevance. J Egypt Public Health Assoc 1995; 70:461–70.
65. Temple M, Renard P, Sanyal S, et al. High circulation of hepatitis E virus in pigs and professionals exposed to pigs in Laos. Zoonoses Public Health 2018; 75:219–31.
66. Shrestha AS, Chongtham AL, Thapa NP, et al. First report of hepatitis E virus viremia in healthy blood donors from Nepal. Virusdisease 2016; 7:324–6.
67. Sedyaningih-Mahamit EH, Larasati RP, Laras et K, et al. First documented outbreak of hepatitis E virus transmission in Java, Indonesia. Trans R Soc Trop Med Hyg 2002; 96:398–404.
68. Qureshi H, Shahid A, Majeed SA. Exposer rate of hepatitis E (IgG) in a selected population of children and adults in Karachi. J Pak Med Assoc 2000; 50:352–4.
69. Gupta BP, Lama TK, Adhikari A, et al. Hepatitis E virus infection among HIV-infected women in an urban area in Tanzania. Int J Infect Dis 2016; 43:375–84.
70. Martinson FE, Marfo YV, Degaaf J. Hepatitis E virus seroprevalence in children living in rural Ghana. West Afr J Med 1999; 18:76–9.
71. Boon D, Reed AD, Laeyendecker O, et al.; Rakai Health Sciences Program. Hepatitis E virus seroprevalence and correlates of anti-HEV IgG antibodies in the Rakai District, Uganda. J Infect Dis 2018; 217:785–9.
72. Ben-Ayed Y, Hannachi H, Ben-Alaya-Bouaif N, et al. Hepatitis E virus seroprevalence among hemodialysis and hemophiliac patients in Tunisia (North Africa). J Med Virol 2015; 87:441–5.
73. Shrestha AC, Flower RL, Seed CR, et al. Hepatitis E virus seroepidemiology: a post-earthquake study among blood donors in Nepal. BMC Infect Dis 2016; 16:707.
74. Amarapurkar D, Agal S, Bajal R, et al. Epidemiology of hepatitis E virus infection in Western India. Hepat Mon 2008; 8:258–62.
98. De Paschale M, Ceriani C, Romanò L, et al. Epidemiology of hepatitis E virus infection during pregnancy in Benin. Trop Med Int Health 2014; 21:108–13.

99. Al Mahtab M, Rahman S, Jahan M, et al. Epidemiology of hepatitis E virus in an urban community in Dhaka city. Hepatol Int. 2013; 7:S277.

100. Labrique AB, Zaman K, Hossain Z, et al. Epidemiology and risk factors of incident hepatitis E virus infections in rural Bangladesh. Am J Epidemiol 2010; 172:952–61.

101. Junaid SA, Agina SE, Abubakar KA. Epidemiology and associated risk factors of hepatitis E virus infection in plateau state, Nigeria. Virology (Auckl) 2014; 5:15–26.

102. Bryan JP, Iqbal M, Tsarev S, et al. Epidemiology of hepatitis E in a military unit in Abbottabad, Pakistan. Am J Trop Med Hyg 2002; 67:66–2.

103. Corwin A, Putri MP, Winarno J, et al. Epidemiology and sporadic hepatitis E virus transmission in West Kalimantan (Borneo), Indonesia. Am J Trop Med Hyg 1997; 56:283–8.

104. Lorenzo AA, De Guzman TS, Su GLS. Detection of IgM and IgG antibodies against hepatitis E virus in donated blood bags from a national voluntary blood bank in Metro Manila, Philippines. Asian Pac J Trop Dis 2015; 5:604–5.

105. Sailaja B, Murhekar MV, Hutin YJ, et al. Outbreak of waterborne hepatitis E in Bangladesh. Emerg Infect Dis 2008; 14:681–3.

106. Siddiqui AR, Joona RA, Smego RA Jr. Nosocomial outbreak of hepatitis E virus infection in Pakistan with possible parenteral transmission. Clin Infect Dis 2005; 40:908–9.

107. Vivek R, Nihal L, Illayaraja J, et al. Investigation of an epidemic of hepatitis E in Nellore in south India. Trop Med Int Health 2010; 15:1333–9.

108. Bouscaillou J, Komas N, Tricou V, et al. Imported hepatitis E virus, Central African Republic, 2011. Emerg Infect Dis 2013; 19:355–7.

109. Bocca D, Guthmann JP, Klovstad H, et al. High mortality associated with an outbreak of hepatitis E among displaced persons in Darfur, Sudan. Clin Infect Dis 2006; 42:1679–84.

110. El-Sayed Zaki M, El-Aal AA, Badawy A, et al. Clinicolaboratory study of mother-child transmission factors, 2016-2017. PLoS One 2017; 12:e0188240.
147. Swain SK, Baral P, Hutin YJ, et al. A hepatitis E outbreak caused by a temporary interruption in a municipal water treatment system, Baripada, Orissa, India, 2004. Trans R Soc Trop Med Hyg 2010; 104:66–9.

148. Aggarwal R, Kumar R, Pal R, et al. Role of travel as a risk factor for hepatitis E virus infection in a disease-endemic area. Indian J Gastroenterol 2002; 21:14–8.

149. Gomatos PJ, Monier MK, Arthur RR, et al. Sporadic acute hepatitis caused by hepatitis E virus in Egyptian adults. Clin Infect Dis 1996; 23:195–6.

150. Ukuli AQ, Mugimba KK. Seroprevalence of hepatitis E in swine abattoir workers. Afr Health Sci 2017; 17:1022–8.

151. Sazzad HMS, Luby SP, Labrique AB, et al. Risk factors associated with blood exposure for sporadic hepatitis E in Dhaka, Bangladesh. Am J Trop Med Hyg 2017; 97:1437–44.

152. Eldin SS, Seddik I, Daef EA, et al. Risk factors and immune response to hepatitis E viral infection among acute hepatitis patients in Assiut, Egypt. Egypt J Immunol 2010; 17:73–86.

153. Howard CM, Handzel T, Hill VR, et al. Novel risk factors associated with hepatitis E virus infection in a large outbreak in Northern Uganda: results from a case-control study and environmental analysis. Am J Trop Med Hyg 2010; 83:1170–3.

154. Bose PD, Das BC, Kumar A, et al. High viral load and deregulation of the progesterone receptor signaling pathway: association with hepatitis E-related poor pregnancy outcome. J Hepatol 2011; 54:1107–13.

155. Hoan NX, Tong HV, Hecht N, et al. Hepatitis E virus superinfection and clinical progression in hepatitis B patients. ElBioMedicine 2015; 2:2080–6.

156. Chau TN, Lai ST, Tee C, et al. Epidemiology and clinical features of sporadic hepatitis E as compared with hepatitis A. Am J Gastroenterol 2006; 101:292–6.

157. Pathak R, Barde PV. Detection of genotype 1a and 1f of hepatitis E virus in patients treated at tertiary care hospitals in Central India. Intervirology 2017; 60:201–6.

158. Labrique AB, Zaman K, Hossain Z, et al. An exploratory case control study of risk factors for hepatitis E in rural Bangladesh. PLoS One 2013; 8:e61351.

159. Shata MT, Daef EA, Zaki ME, et al. Protective role of humoral immune responses during an outbreak of hepatitis E in Egypt. Trans R Soc Trop Med Hyg 2012; 106:613–8.

160. Li P, Liu J, Li Y, et al. The global epidemiology of hepatitis E virus infection: a systematic review and meta-analysis. Liver Int 2020; 40:1516–28.

161. Hakim MS, Wang W, Bramer WM, et al. The global burden of hepatitis E outbreaks: a systematic review. Available at: https://onlinelibrary.wiley.com/doi/full/10.1111/liv.13237. Accessed 10 November 2020.

162. Kim JH, Nelson KE, Panzner U, et al. A systematic review of the epidemiology of hepatitis E virus in Africa. BMC Infect Dis 2014; 14:308.

163. Azman AS, Giglenci I, Wamala JF, et al. Hepatitis E should be considered a neglected tropical disease. PLoS Negl Trop Dis 2019; 13:e0007453.

164. Chen X, Chen Z, Azman AS, et al. Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis. Lancet Glob Health 2021; 9:E598–609.

165. Mina MJ, Metcalf CJ, McDermott AB, et al. A Global Immunological Observatory to meet a time of pandemics. eLife 2020; 9:e58989.

166. Chyou PH. Patterns of bias due to differential misclassification by case-control status in a case-control study. Eur J Epidemiol 2007; 22:7–17.

167. Azman AS, Bouhenia M, Iyer AS, et al. High hepatitis E seroprevalence among displaced persons in South Sudan. Am J Trop Med Hyg 2017; 96:1296–301.